Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study

Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study

To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged ≥60 years. In this phase III, randomized, double-blind, active-controlled trial, we compared safety and...

Full description

Bibliographic Details
Main Authors: Renfeng Fan, Xiaoyuan Huang, Xuanxuan Nian, Zhiqiang Ou, Jian Zhou, Jiayou Zhang, Peiyu Zeng, Wei Zhao, Jinglong Deng, Wei Chen, Shaomin Chen, Kai Duan, Yingshi Chen, Xinguo Li, Jikai Zhang, Xiaoming Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
seasonal influenza
vaccine
quadrivalent
immunogenicity
tolerability
Online Access:http://dx.doi.org/10.1080/21645515.2021.1967041

Internet

http://dx.doi.org/10.1080/21645515.2021.1967041

Similar Items